Stocks edge higher as yields retreat; healthcare leads while chips lag

A pullback in Treasury yields helped U.S. equities snap a three‑day dip, though early strength faded into the close. Healthcare led on upbeat cancer-therapy data, while semiconductors and AI infrastructure remained a drag. Traders also kept one eye on the Fed minutes, tempering risk after the initial rates-driven relief rally.

Key Headlines & Market Movers

Treasury buyback tweak cools yields, rally then pares: The U.S. Treasury signaled it will buy more long‑dated bonds, easing pressure in rates and giving equities an early lift. Benchmark yields slipped on the announcement, loosening the tight financial conditions that had been weighing on risk assets. Into the afternoon, gains moderated as profit‑taking set in and investors acknowledged that the longer‑term rates debate isn’t settled by a single operations tweak.

Healthcare steals the show on late‑stage cancer trial win: Moderna and Merck rallied after reporting that a personalized mRNA therapy reduced melanoma recurrence and spread in a late‑stage study, igniting a broad bid in healthcare. The move provided welcome sector leadership on a day when index gains were otherwise modest. Positive drug data can be idiosyncratic, but the scale of today’s move shifted market tone and diversified leadership beyond mega‑cap tech.

AI complex and chips still heavy, with global tech under strain: Despite relief from rates, chipmakers and AI infrastructure names stayed on the back foot, capping the Nasdaq’s advance. Overseas, weakness in Asia’s tech-heavy markets underscored the fragility of the recent AI run and the sensitivity of high‑duration growth to rate swings. The divergence—defensive healthcare up, cyclical tech mixed—kept breadth uneven.

Focus turns to the Fed minutes for clues on how officials weigh sticky inflation against growth and financial conditions, and whether the buyback-fueled easing in yields has legs. Watch if healthcare leadership broadens and whether semis can stabilize; if rates drift lower but leadership narrows, expect choppier tape until earnings or policy deliver a clearer catalyst.

Disclaimer

Duncan Williams Asset Management is an SEC registered investment adviser. SEC registration does not constitute an endorsement of Duncan Williams Asset Management by the SEC nor does it indicate that Duncan Williams Asset Management has attained a particular level of skill or ability.

This material prepared by Duncan Williams Asset Management is for informational purposes only and is accurate as of the date it was prepared.  It is not intended to serve as a substitute for personalized investment advice or as a recommendation or solicitation of any particular security, strategy or investment product. Past performance is not indicative of future results. Investing involves risks, including the risk of loss of principal. Before making any investment decision, investors should consult with their financial advisor, consider their individual financial circumstances, and carefully review all relevant information and risk factors. Duncan Williams Asset Management assumes no responsibility for errors or omissions, nor does it accept liability for any loss arising from reliance on this information.

Advisory services are only offered to clients or prospective clients where Duncan Williams Asset Management and its representatives are properly licensed or exempt from licensure. No advice may be rendered by Duncan Williams Asset Management unless a client service agreement is in place.

This material is not intended to serve as personalized tax, legal and/or investment advice since the availability and effectiveness of any strategy is dependent upon your individual facts and circumstances. Duncan Williams Asset Management is not a legal or accounting firm. Please consult with your legal or tax professional regarding your specific tax situation when determining if any of the mentioned strategies are right for you.

‍